SE363094

1,233,354. Benzenesulphonyl-ureas. FARBWERKE HOECHST A.G. 14 Feb., 1969 [2 Aug., 1968], No. 8218/69. Heading C2C. Novel compounds I (including salts thereof) wherein X signifies the groups II or III in which R signifies C 1-4 alkyl, Z signifies halogen, C 1-4 alkyl or C 1-4 alkoxy and Z1 signifies halogen or C 1-4 alkyl are obtained according to standard methods. N - [4 - (# - Aminoethyl) - benzenesulphonyl]. N1 - (#2 - cyclohexenyl) - urea is prepared by saponifying the #-acetamidoethyl-compound. 1 - [4 - (# - < 2 - Methoxy - 5 - chlorobenzamido > - ethyl) - benzenesulphonyl] - 3 - (#2. cyclohexenyl)-parabanic acid is prepared by the interaction of 1-(#2-cyclohexenyl)-parabanic acid and 4 - (# - < 2 - methoxy - 5 - chlorobenzamido > - ethyl) - benzenesulphochloride. #2 - Cyclohexenyl isocyanate is prepared by heating N - (#2 - cyclohexenyl) - N1,N1 - diphenyl-urea. The cyclohexenylamine salt of N-[4 - (# - < 2- methoxy - 5 - chlorobenzamido > - ethyl) - benzenesulphonyl] - N1 - aceryl - urea is obtained by mixing the individual compounds and heating. N - (#2 - Cyclohexenyl) - carbamic acid phenyl ester is prepared by the interaction of phenyl chloroformate and #2-cyclohexenylamine. N - Acetyl - N1 - (#2 - cyclohexenyl) - urea is prepared by the interaction of acetic anhydride and #2-cyclohexenyl-urea. N,N - Diphenyl - N1 - (#2 - cyclohexenyl)- urea is prepared from diphenyl carbamoyl chloride and #2-cyclohexenylamine. N,N1 - Di - (#2 - cyclohexenyl) - urea is prepared from #2 - cyclohdxenyl isocyanate and #2-cyclohexenylamine. N - [4 - (# - < 2 - Methoxy - 5 - chlorobenzamido > - ethyl) - benzenesulphonyl] - phenylurethane, -N1N1 - diphenyl - urea, - iminodithio - carbonic acid potassium salt and dimethyl ester, -N1 - (#2 - cyclohexenyl) - isothiourea methyl ether, -N1-(#2-cyclohexenyl)- thiourea and - N1 - (#2 - cyclohexenyl) - isourea methyl ether and 4-(#- - ethyl) - benzene sulphonamide are also prepared as intermediates. Pharmaceutical preparations exhibiting blood sugar lowering properties and hypoglycemic activity contain I as active ingredient; administration is orally.